ProShare Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-38,865
Closed -$17.6K 2135
2025
Q1
$17.6K Sell
38,865
-2,741
-7% -$1.61K ﹤0.01% 2045
2024
Q4
$20.9K Buy
41,606
+13,691
+49% +$10.1K ﹤0.01% 2254
2024
Q3
$25.3K Buy
27,915
+10,141
+57% +$9.4K ﹤0.01% 2032
2024
Q2
$17.7K Sell
17,774
-6,067
-25% -$6.7K ﹤0.01% 1813
2024
Q1
$35.3K Buy
23,841
+1,877
+9% +$2.13K ﹤0.01% 1947
2023
Q4
$23.9K Buy
21,964
+5,198
+31% +$5.69K ﹤0.01% 1912
2023
Q3
$19.8K Sell
16,766
-18
-0.1% -$24 ﹤0.01% 1788
2023
Q2
$23.7K Buy
+16,784
New +$23.2K ﹤0.01% 1829
2022
Q2
Sell
-23,513
Closed -$36K 1974
2022
Q1
$36K Sell
23,513
-3,884
-14% -$6.03K ﹤0.01% 2138
2021
Q4
$67K Buy
27,397
+11,326
+70% +$26.5K ﹤0.01% 2249
2021
Q3
$40K Sell
16,071
-15,388
-49% -$39.5K ﹤0.01% 1973
2021
Q2
$90K Buy
+31,459
New +$81.4K ﹤0.01% 2306
2020
Q1
Sell
-14,661
Closed -$13K 1398
2019
Q4
$13K Buy
14,661
+2,343
+19% +$1.95K ﹤0.01% 1784
2019
Q3
$12K Buy
12,318
+359
+3% +$372 ﹤0.01% 1652
2019
Q2
$13K Sell
11,959
-314
-3% -$362 ﹤0.01% 1616
2019
Q1
$16K Buy
+12,273
New +$15.3K ﹤0.01% 1650
2018
Q4
Sell
-12,522
Closed -$26K 1641
2018
Q3
$26K Sell
12,522
-962
-7% -$2.02K ﹤0.01% 1749
2018
Q2
$24K Buy
13,484
+829
+7% +$1.67K ﹤0.01% 1785
2018
Q1
$30K Sell
12,655
-2,042
-14% -$4.79K ﹤0.01% 1698
2017
Q4
$28K Buy
+14,697
New +$32.1K ﹤0.01% 1787
2017
Q1
Sell
-12,768
Closed -$40K 1614
2016
Q4
$40K Buy
+12,768
New +$39.2K ﹤0.01% 1719
2015
Q2
Sell
-12,457
Closed -$50K 1722
2015
Q1
$50K Sell
12,457
-1,389
-10% -$4.81K ﹤0.01% 1869
2014
Q4
$42K Sell
13,846
-11,773
-46% -$31.8K ﹤0.01% 1926
2014
Q3
$65K Sell
25,619
-5,801
-18% -$14K ﹤0.01% 2229
2014
Q2
$77K Sell
31,420
-14,907
-32% -$33.7K ﹤0.01% 2408
2014
Q1
$123K Buy
+46,327
New +$136K ﹤0.01% 2651
2013
Q4
Sell
-28,904
Closed -$89K 1616
2013
Q3
$89K Buy
28,904
+1,623
+6% +$5.14K ﹤0.01% 2442
2013
Q2
$87K Buy
+27,281
New +$87.4K ﹤0.01% 2285

Other funds holding LCTX